文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

中国武汉COVID-19肺炎患者急性呼吸窘迫综合征与死亡的相关危险因素

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.
PubMed 文献 · JAMA Intern Med · 2020-01-01
一句话结论回顾性队列显示高龄、中性粒细胞增多、器官及凝血功能障碍与COVID-19肺炎发生ARDS及死亡相关,甲泼尼龙可能降低ARDS患者死亡风险。

该回顾性队列纳入2019年12月25日至2020年1月26日武汉金银潭医院201例确诊COVID-19肺炎患者,随访至2020年2月13日。84例(41.8%)发生ARDS,其中44例(52.4%)死亡。发生ARDS者较未发生者更多出现呼吸困难(59.5% vs 25.6%)及高血压、糖尿病等合并症。双变量Cox回归中,高龄、中性粒细胞增多、乳酸脱氢酶升高和D-二聚体升高与ARDS发生及ARDS进展至死亡相关;高热(≥39°C)与ARDS发生风险升高相关但与死亡风险降低相关;ARDS患者接受甲泼尼龙治疗与死亡风险降低相关(HR 0.38)。

要点

  • 201例COVID-19肺炎患者中84例(41.8%)发生ARDS,其中44例(52.4%)死亡。
  • 发生ARDS者较未发生者更多有呼吸困难(59.5% vs 25.6%,差值33.9%,95%CI 19.7%-48.1%)。
  • 双变量Cox回归中高龄与ARDS发生(HR 3.26,95%CI 2.08-5.11)及ARDS进展至死亡(HR 6.17,95%CI 3.26-11.67)相关。
  • 高热(≥39°C)与ARDS发生风险升高相关(HR 1.77,95%CI 1.11-2.84),但与死亡风险降低相关(HR 0.41,95%CI 0.21-0.82)。
  • ARDS患者接受甲泼尼龙治疗与死亡风险降低相关(HR 0.38,95%CI 0.20-0.72)。

适用人群与场景

  • 2019年12月25日至2020年1月26日入住武汉金银潭医院的确诊COVID-19肺炎患者201例,中位年龄51岁(四分位距43-60岁),男性128例(63.7%)。

处置流程与药物剂量

  • ARDS患者中,甲泼尼龙治疗与死亡风险降低相关(HR 0.38,95%CI 0.20-0.72);原文未报告甲泼尼龙的具体剂量、给药途径、频次或疗程。

研究设计与关键结果

  • 回顾性队列研究,201例确诊COVID-19肺炎患者,84例(41.8%)发生ARDS,其中44例(52.4%)死亡。
  • 发生ARDS者较未发生者更多出现呼吸困难(50/84[59.5%] vs 30/117[25.6%],差值33.9%,95%CI 19.7%-48.1%)、高血压(23/84[27.4%] vs 16/117[13.7%],差值13.7%,95%CI 1.3%-26.1%)和糖尿病(16/84[19.0%] vs 6/117[5.1%],差值13.9%,95%CI 3.6%-24.2%)。
  • 双变量Cox回归中,与ARDS发生及ARDS进展至死亡相关的因素包括高龄(HR 3.26,95%CI 2.08-5.11;HR 6.17,95%CI 3.26-11.67)、中性粒细胞增多(HR 1.14,95%CI 1.09-1.19;HR 1.08,95%CI 1.01-1.17)、乳酸脱氢酶升高(HR 1.61,95%CI 1.44-1.79;HR 1.30,95%CI 1.11-1.52)和D-二聚体升高(HR 1.03,95%CI 1.01-1.04;HR 1.02,95%CI 1.01-1.04)。
  • 高热(≥39°C)与ARDS发生风险升高相关(HR 1.77,95%CI 1.11-2.84),与死亡风险降低相关(HR 0.41,95%CI 0.21-0.82)。
  • ARDS患者中,甲泼尼龙治疗与死亡风险降低相关(HR 0.38,95%CI 0.20-0.72)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,高龄可能与较弱的免疫反应有关,从而与ARDS发生和死亡风险增加相关。
  • 作者认为,高热(≥39°C)虽与ARDS发生相关,但在ARDS患者中与较好的结局相关。
  • 作者认为,甲泼尼龙治疗可能对发生ARDS的患者有益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and has subsequently spread worldwide. Risk factors for the clinical outcomes of COVID-19 pneumonia have not yet been well delineated.

OBJECTIVE: To describe the clinical characteristics and outcomes in patients with COVID-19 pneumonia who developed acute respiratory distress syndrome (ARDS) or died.

DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of 201 patients with confirmed COVID-19 pneumonia admitted to Wuhan Jinyintan Hospital in China between December 25, 2019, and January 26, 2020. The final date of follow-up was February 13, 2020.

EXPOSURES: Confirmed COVID-19 pneumonia.

MAIN OUTCOMES AND MEASURES: The development of ARDS and death. Epidemiological, demographic, clinical, laboratory, management, treatment, and outcome data were also collected and analyzed.

RESULTS: Of 201 patients, the median age was 51 years (interquartile range, 43-60 years), and 128 (63.7%) patients were men. Eighty-four patients (41.8%) developed ARDS, and of those 84 patients, 44 (52.4%) died. In those who developed ARDS, compared with those who did not, more patients presented with dyspnea (50 of 84 [59.5%] patients and 30 of 117 [25.6%] patients, respectively [difference, 33.9%; 95% CI, 19.7%-48.1%]) and had comorbidities such as hypertension (23 of 84 [27.4%] patients and 16 of 117 [13.7%] patients, respectively [difference, 13.7%; 95% CI, 1.3%-26.1%]) and diabetes (16 of 84 [19.0%] patients and 6 of 117 [5.1%] patients, respectively [difference, 13.9%; 95% CI, 3.6%-24.2%]). In bivariate Cox regression analysis, risk factors associated with the development of ARDS and progression from ARDS to death included older age (hazard ratio [HR], 3.26; 95% CI 2.08-5.11; and HR, 6.17; 95% CI, 3.26-11.67, respectively), neutrophilia (HR, 1.14; 95% CI, 1.09-1.19; and HR, 1.08; 95% CI, 1.01-1.17, respectively), and organ and coagulation dysfunction (eg, higher lactate dehydrogenase [HR, 1.61; 95% CI, 1.44-1.79; and HR, 1.30; 95% CI, 1.11-1.52, respectively] and D-dimer [HR, 1.03; 95% CI, 1.01-1.04; and HR, 1.02; 95% CI, 1.01-1.04, respectively]). High fever (≥39 °C) was associated with higher likelihood of ARDS development (HR, 1.77; 95% CI, 1.11-2.84) and lower likelihood of death (HR, 0.41; 95% CI, 0.21-0.82). Among patients with ARDS, treatment with methylprednisolone decreased the risk of death (HR, 0.38; 95% CI, 0.20-0.72).

CONCLUSIONS AND RELEVANCE: Older age was associated with greater risk of development of ARDS and death likely owing to less rigorous immune response. Although high fever was associated with the development of ARDS, it was also associated with better outcomes among patients with ARDS. Moreover, treatment with methylprednisolone may be beneficial for patients who develop ARDS.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020. PMID: 32167524. doi:10.1001/jamainternmed.2020.0994

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。